United Advisor Group LLC Lowers Holdings in Amgen Inc. (NASDAQ:AMGN)

United Advisor Group LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 22.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 921 shares of the medical research company’s stock after selling 261 shares during the quarter. United Advisor Group LLC’s holdings in Amgen were worth $287,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Centricity Wealth Management LLC acquired a new position in Amgen during the 4th quarter valued at approximately $25,000. Pinney & Scofield Inc. purchased a new stake in Amgen in the fourth quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE increased its holdings in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC purchased a new position in Amgen during the 4th quarter worth approximately $34,000. Finally, Atala Financial Inc acquired a new stake in Amgen during the 4th quarter valued at approximately $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Royal Bank Of Canada dropped their target price on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on shares of Amgen in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $305.00 target price for the company. UBS Group reissued a “neutral” rating and set a $315.00 target price (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Guggenheim started coverage on Amgen in a research report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 target price on the stock. Finally, Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $309.22.

Amgen Stock Down 0.1%

AMGN opened at $289.33 on Friday. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. The company has a market cap of $155.58 billion, a price-to-earnings ratio of 26.40, a PEG ratio of 2.62 and a beta of 0.51. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The business’s fifty day moving average is $281.82 and its two-hundred day moving average is $285.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the prior year, the firm earned $3.96 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.